U.S. License Holder:
Biogen Inc.
Date of License:
June-07-2021
Last Update:
Dec-15-2024
FDA-Approved Indications
ADUHELM (aducanumab-avwa) is an amyloid beta-directed antibody indicated for the treatment of Alzheimer's disease. Treatment with Aduhelm should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied.